ReviewAnnals of translational medicine2019
Conversion therapy from N3 unresectable lung adenocarcinoma to radical surgery: a case report.
Review in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Surgery After Induction Immuno-Chemotherapy in Stage III-N3 Non-Small Cell Lung Cancer: A Single-Centre Retrospective Cohort Study.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- Opportunities and challenges of immunotherapy for patients with resectable and potentially resectable stage III non-small cell lung cancer.Cancer biology & medicine · 2026Review
- Case Report: Long-term TCR repertoire dynamics in a disease-free survival stage IIIB-N3 lung adenocarcinoma patient treated with anti-PD-1 followed by surgery.Frontiers in immunology · 2026Article
- Article
- Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgeryFrontiers in oncology · 2022Article
- The power of immunotherapy plus platinum-based chemotherapy for locally advanced or early stage non-small cell lung cancer.Annals of translational medicine · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with N3 non-small cell lung cancer (NSCLC) have unresectable tumors. Although significant progress has been made in the past decades for such tumors, the average median survival time remains at 10 months. Equally dismal long-term survival rates were reported with the average 5-year-suvival rate at 9%. Here, we report on a case of a patient with locally advanced disease that was treated with conversion therapy using targeted anti-PD-1 immunotherapy with platinum-based chemotherapy. Following this therapeutic regimen, the tumor showed a reversion to pN0 from pN3 and the patient showed a progression free survival time of at least 33 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.